Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9864613 | 0.77 | NPC1 (0.37) | NPC1RAB9ATSHRALDH1A1LMNA | |
| SCHEMBL8572530 | 0.74 | NPC1 (0.37) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL91381 | 0.72 | — | — | |
| SCHEMBL2916887 | 0.70 | NOS2 (0.40) | TSHRNOS2ALDH1A1 | |
| SCHEMBL15189833 | 0.70 | NPC1 (0.34) | NPC1RAB9AMAPTHTTHSD17B10 | |
| SCHEMBL24951839 | 0.68 | TSHR (0.48) | NPC1RAB9ATSHRALDH1A1LMNA | |
| SCHEMBL4939076 | 0.68 | — | — | |
| SCHEMBL1080895 | 0.68 | ALDH1A1 (0.47) | NPC1RAB9ATSHRALDH1A1LMNA | |
| SCHEMBL353108 | 0.67 | — | — | |
| SCHEMBL1082406 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | disclosed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | disclosed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | NPC1 409/4885RAB9A 3685/4885TSHR 4126/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | NPC1 411/4885RAB9A 3924/4885TSHR 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.